Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 6.5% – Should You Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s stock price dropped 6.5% on Thursday . The company traded as low as $9.52 and last traded at $10.16. Approximately 24,316,392 shares traded hands during mid-day trading, a decline of 4% from the average daily volume of 25,259,420 shares. The stock had previously closed at $10.87.

Analyst Ratings Changes

Several equities research analysts recently weighed in on RXRX shares. KeyCorp reduced their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a report on Wednesday, January 8th. Needham & Company LLC restated a “buy” rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th.

Recursion Pharmaceuticals Price Performance

The stock’s 50 day moving average price is $7.56 and its two-hundred day moving average price is $7.02. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The firm has a market capitalization of $3.63 billion, a price-to-earnings ratio of -6.07 and a beta of 0.86.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in Recursion Pharmaceuticals by 40.1% during the 4th quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company’s stock valued at $229,908,000 after purchasing an additional 9,737,196 shares during the last quarter. ARK Investment Management LLC raised its stake in Recursion Pharmaceuticals by 16.4% during the 3rd quarter. ARK Investment Management LLC now owns 32,769,186 shares of the company’s stock valued at $215,949,000 after purchasing an additional 4,626,268 shares during the last quarter. Softbank Group CORP. acquired a new position in Recursion Pharmaceuticals during the 4th quarter valued at $99,152,000. State Street Corp raised its stake in Recursion Pharmaceuticals by 47.1% during the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company’s stock valued at $84,815,000 after purchasing an additional 4,120,685 shares during the last quarter. Finally, Novo Holdings A S acquired a new position in Recursion Pharmaceuticals during the 4th quarter valued at $68,375,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.